OTCMKTS:PTEO

Proteo SEC Filings & 10K Form

$0.09
0.00 (0.00 %)
(As of 06/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.09
$0.09
50-Day Range
$0.09
$179.80
52-Week Range
$20.00
$698.00
VolumeN/A
Average Volume11 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Proteo (OTCMKTS:PTEO) SEC Filings

DateFilerForm TypeView
07/22/2020
3:33 PM
Proteo (Subject)
Form SC 13E3/A
07/22/2020
3:30 PM
Proteo (Filer)
Form 15-12G
07/20/2020
3:05 PM
Proteo (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/10/2020
7:00 AM
Proteo (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/26/2020
2:32 PM
Proteo (Filer)
Form DEFA14A
05/26/2020
1:47 PM
Proteo (Subject)
Form SC 13E3/A
05/26/2020
8:17 AM
Proteo (Filer)
Form DEFR14A
05/18/2020
11:21 AM
Proteo (Filer)
Form DEF 14A
05/07/2020
3:32 PM
Proteo (Subject)
Form SC 13E3
05/07/2020
3:30 PM
Proteo (Filer)
Form PRE 14A
03/30/2020
7:09 AM
Proteo (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/11/2020
1:06 PM
Proteo (Subject)
Siebuhr Diethelm Achim DA (Filed by)
Form SC 13G
03/11/2020
1:06 PM
Bartels Kai Dieter (Filed by)
Proteo (Subject)
Form SC 13G
03/11/2020
1:05 PM
Proteo (Issuer)
Siebuhr Diethelm Achim DA (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/11/2020
1:04 PM
Bartels Kai Dieter (Reporting)
Proteo (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
11/14/2019
2:06 PM
Proteo (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/05/2019
1:18 PM
Proteo (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2019
3:28 PM
Proteo (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/15/2019
3:39 PM
Proteo (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
04/11/2019
12:16 PM
Proteo (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/01/2019
8:44 AM
Proteo (Filer)
Form NT 10-K
12/14/2018
3:05 PM
Proteo (Issuer)
VON REDEN JORK (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/14/2018
3:05 PM
Proteo (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2018
8:24 PM
Proteo (Issuer)
VON REDEN JORK (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/31/2018
3:15 PM
Proteo (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2018
2:03 PM
Proteo (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/21/2018
2:43 PM
Proteo (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/27/2018
2:04 PM
Proteo (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
04/02/2018
7:27 AM
Proteo (Filer)
Form NT 10-K
This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.